# Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer

> **NCT06519292** · — · RECRUITING · sponsor: **Hanneke W. M. van Laarhoven** · enrollment: 214 (estimated)

## Conditions studied

- Cardiovascular Diseases
- Arterial Thrombosis
- Myocardial Infarction
- Stroke
- Coronary Artery Disease
- Atherosclerosis
- Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Coronary computed tomography angiography (CCTA) at baseline
- **DIAGNOSTIC_TEST:** Coronary computed tomography angiography (CCTA) after 1 year

## Key facts

- **NCT ID:** NCT06519292
- **Lead sponsor:** Hanneke W. M. van Laarhoven
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-25
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 214 (ESTIMATED)
- **Last updated:** 2025-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06519292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06519292, "Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06519292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*